LLY vs SLRX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

SLRX (Salarius Pharmaceuticals, Inc.) was acquired by VolitionRx Limited (VNRX) on October 18, 2023, and subsequently delisted. As of today, 2026-03-29, it does not exist as an independent publicly traded entity with any growth prospects. The quoted current price of $7.62 is an anomaly for a delisted ticker and does not reflect a liquid, investable asset. There have been no material changes since ...